AstraZeneca PLC (ADR) Scores High in Guru Growth Model

AstraZeneca PLC (ADR) shines with a 77% rating in a growth model. This high score reflects strong fundamentals and potential for sustained growth, positioning it positively in the market.

Date: 24-02-2025

AI Rating: 7

AstraZeneca PLC (ADR) Analysis

AstraZeneca PLC (ADR) has garnered a significant rating of 77% in the P/B Growth Investor model, indicating a solid interest based on the company's fundamentals and stock valuation. This score suggests that AstraZeneca is considered a strong candidate for investors looking for growth potential.

Key Metrics and Ratings

The performance metrics in the report reveal that AstraZeneca meets several criteria effectively:

Book/Market Ratio: PASS
Return on Assets: PASS
Cash Flow from Operations to Assets: PASS
Cash Flow from Operations to Assets vs. Return on Assets: PASS
Return on Assets Variance: PASS
Sales Variance: PASS
Capital Expenditures to Assets: PASS

However, the report notes two criteria where AstraZeneca did not meet the expectations:

Advertising to Assets: FAIL
Research and Development to Assets: FAIL

While the strong performance in the majority of metrics indicates positive strength and may boost investor confidence, the failures in advertising and R&D spending may raise concerns regarding innovation and market positioning in the long term.

Overall, the mixed results illustrate a company that has significant growth potential but also faces challenges that could affect investor sentiment in the biotechnology sector.

Stocks: AZN